COX-2 inhibitors and cardiovascular risk: Point and counterpoint

Brian F. Mandell, MD, PhD
Department of Rheumatic and Immunologic Diseases and Senior Associate Program Director, Internal Medicine Residency Program, Cleveland Clinic; Deputy Editor, Cleveland Clinic Journal of Medicine

Address: Brian F. Mandell, MD, PhD, FACR, Cleveland Clinic Journal of Medicine, NA32,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Mandell has received honoraria, research support, or donations to educational programs from the Centocor, Merck, Pfizer, Searle, SmithKline Beecham, and Wyeth Pharmaceutical corporations.

Brian F. Mandell, MD, PhD
Department of Rheumatic and Immunologic Diseases and Senior Associate Program Director, Internal Medicine Residency Program, Cleveland Clinic; Deputy Editor, Cleveland Clinic Journal of Medicine

Address: Brian F. Mandell, MD, PhD, FACR, Cleveland Clinic Journal of Medicine, NA32,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Mandell has received honoraria, research support, or donations to educational programs from the Centocor, Merck, Pfizer, Searle, SmithKline Beecham, and Wyeth Pharmaceutical corporations.

Brian F. Mandell, MD, PhD
Department of Rheumatic and Immunologic Diseases and Senior Associate Program Director, Internal Medicine Residency Program, Cleveland Clinic; Deputy Editor, Cleveland Clinic Journal of Medicine

Address: Brian F. Mandell, MD, PhD, FACR, Cleveland Clinic Journal of Medicine, NA32,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Dr. Mandell has received honoraria, research support, or donations to educational programs from the Centocor, Merck, Pfizer, Searle, SmithKline Beecham, and Wyeth Pharmaceutical corporations.